Efficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyond

Simple item page
dc.contributor.authorMills, Susanen
dc.contributor.authorYang, Boen
dc.contributor.authorSmith, Graeme J.en
dc.contributor.authorStanton, Catherineen
dc.contributor.authorRoss, R. Paulen
dc.contributor.funderScience Foundation Irelanden
dc.date.accessioned2024-03-12T12:16:06Z
dc.date.available2024-03-12T12:16:06Z
dc.date.issued2023en
dc.description.abstractThe significance of Bifidobacterium to human health can be appreciated from its early colonization of the neonatal gut, where Bifidobacterium longum represents the most abundant species. While its relative abundance declines with age, it is further reduced in several diseases. Research into the beneficial properties of B. longum has unveiled a range of mechanisms, including the production of bioactive molecules, such as short-chain fatty acids, polysaccharides, and serine protease inhibitors. From its intestinal niche, B. longum can have far-reaching effects in the body influencing immune responses in the lungs and even skin, as well as influencing brain activity. In this review, we present the biological and clinical impacts of this species on a range of human conditions beginning in neonatal life and beyond. The available scientific evidence reveals a strong rationale for continued research and further clinical trials that investigate the ability of B. longum to treat or prevent a range of diseases across the human lifespan.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid2186098en
dc.identifier.citationMills, S., Yang, B., Smith, G.J., Stanton, C. and Ross, R.P. (2023) ‘Efficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyond’, Gut Microbes, 15(1), 2186098 (41pp). doi:10.1080/19490976.2023.2186098en
dc.identifier.doi10.1080/19490976.2023.2186098en
dc.identifier.eissn1949-0984en
dc.identifier.endpage41en
dc.identifier.issn1949-0976en
dc.identifier.issued1en
dc.identifier.journaltitleGut Microbesen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/15661
dc.identifier.volume15en
dc.language.isoenen
dc.publisherTaylor and Francis Ltd.en
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2273/IE/Alimentary Pharmabiotic Centre (APC) - Interfacing Food & Medicine/en
dc.rights© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectBifidobacteriumen
dc.subjectBifidobacterium longum ssp. infantisen
dc.subjectBifidobacterium longum ssp. longumen
dc.subjectHealthen
dc.subjectNeonateen
dc.subjectProbioticen
dc.subjectGut microbiotaen
dc.subjectNecrotizing enterocolitisen
dc.subjectCardiovascular diseaseen
dc.subjectImmunityen
dc.subjectCognitive impairmenten
dc.titleEfficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyonden
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Efficacy of Bifidobacterium longum alone or in multi-strain probiotic formulations during early life and beyond.pdf
Size:
2.29 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
APC Microbiome Ireland - Journal Articles